Rivaroxaban (Xarelto) in the management of stroke and DVT

S Chaplin; V Haunton; T Robinson; C Bagot

doi:10.1002/psb.950

Rivaroxaban (Xarelto) in the management of stroke and DVT

S Chaplin
, V Haunton
, T Robinson
, C Bagot

Peninsula Medical School

Research output: Contribution to journal › Article › peer-review

Abstract

AbstractRivaroxaban is now licensed for the prevention of stroke and the treatment and prevention of DVT. In our New products review, Steve Chaplin presents the clinical data for its efficacy and adverse events related to these new indications, and specialists comment on its likely place in therapy.

Original language	English
Pages (from-to)	14-23
Number of pages	0
Journal	Prescriber
Volume	23
Issue number	17
DOIs	https://doi.org/10.1002/psb.950
Publication status	Published - 5 Sept 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1002/psb.950

Cite this

@article{18dd695da48940eeb07b502bcd769ee2,

title = "Rivaroxaban (Xarelto) in the management of stroke and DVT",

abstract = "AbstractRivaroxaban is now licensed for the prevention of stroke and the treatment and prevention of DVT. In our New products review, Steve Chaplin presents the clinical data for its efficacy and adverse events related to these new indications, and specialists comment on its likely place in therapy.",

author = "S Chaplin and V Haunton and T Robinson and C Bagot",

year = "2012",

month = sep,

day = "5",

doi = "10.1002/psb.950",

language = "English",

volume = "23",

pages = "14--23",

journal = "Prescriber",

issn = "0959-6682",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "17",

}

TY - JOUR

T1 - Rivaroxaban (Xarelto) in the management of stroke and DVT

AU - Chaplin, S

AU - Haunton, V

AU - Robinson, T

AU - Bagot, C

PY - 2012/9/5

Y1 - 2012/9/5

N2 - AbstractRivaroxaban is now licensed for the prevention of stroke and the treatment and prevention of DVT. In our New products review, Steve Chaplin presents the clinical data for its efficacy and adverse events related to these new indications, and specialists comment on its likely place in therapy.

AB - AbstractRivaroxaban is now licensed for the prevention of stroke and the treatment and prevention of DVT. In our New products review, Steve Chaplin presents the clinical data for its efficacy and adverse events related to these new indications, and specialists comment on its likely place in therapy.

U2 - 10.1002/psb.950

DO - 10.1002/psb.950

M3 - Article

SN - 0959-6682

VL - 23

SP - 14

EP - 23

JO - Prescriber

JF - Prescriber

IS - 17

ER -

Rivaroxaban (Xarelto) in the management of stroke and DVT

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this